<DOC>
	<DOCNO>NCT02732275</DOCNO>
	<brief_summary>This First-in-Human , Phase 1 , multi-center , non-randomized , open label study DS-3201b , Histone-lysine N-methyltransferase EZH1/2 dual inhibitor ass safety tolerability , identify maximum tolerate dose ( MTD ) / tentative recommend phase 2 dose ( RP2D ) , assess pharmacokinetic/dynamic property Japanese subject Non-Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>A Phase 1 Multiple Ascending Dose Study DS-3201b Japanese Subjects With Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<criteria>Has cytologically pathologically document non hodgkin 's lymphoma ( NHL ) Subjects relapsed refractory standard treatment standard treatment available . Age ≥ 20 year time inform consent . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 screening . Has least one target lesion . Has adequate organ function , define : Platelet count &gt; = 75 x 109/L , Absolute neutrophil count &gt; = 1.0 x 109/L , Creatinine clearance &gt; = 60 mL/min , AST/ALT level = &lt; 3 x ULN , Bilirubin = &lt; 1.5 x ULN . ULN = upper limit normal AST = aspartate transaminase ALT = alanine transaminase Has leukemia , precursor Tcell lymphoblastic leukemia , Tcell lymphoblastic leukemia , Tcell acute lymphoblastic leukemia , Tcell prolymphocytic leukemia , Tcell large granular lymphocytic leukemia Has history central nervous system ( CNS ) symptom , diagnose CNS lymphoma Previously ( within 6 month registration ) currently follow disease : uncontrolled diabetes mellitus , cardiac failure ( The New York Heart Association [ NYHA ] Functional Classification ≥ Class III ) , myocardial infarction , cerebral infarction , unstable angina , arrhythmia require treatment , coronary/peripheral bypass surgery , pulmonary thrombosis , uncontrolled deep vein thrombosis , clinically severe thromboembolic event , autoimmune disease require treatment . Has history myocardial infarction unstable angina within 6 month registration ; symptomatic congestive heart failure ( CHF ; NYHA class IIIIV ) ; congenital long QT syndrome ; ventricular arrhythmia require treatment . Grade 4 neuropathy Has QTcF prolongation &gt; 450 m base triplicate ECG screening . Clinically severe infection require systemic administration antibacterial antiviral agent . Positive following : active infection human hepatitis B surface ( HBs ) antigen , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) antibody within 90 day registration . Positive following : human hepatitis B core ( HBc ) antibody , human HBs antibody ≥ 2.1 log copies/mL hepatitis B virus ( HBV ) DNA within 90 day registration . Has concomitant neuropsychiatric disorder would increase risk toxicity , opinion investigator . Has history allogeneic hematopoietic stem cell transplantation . Has receive autologous hematopoietic stem cell transplantation within 12 week ( 84 day ) start study treatment . Has receive investigational drug within 4 week ( 28 day ) start study treatment . Has receive chemotherapy immunotherapy ( include target therapy antibody small molecule , retinoid therapy , hormonal therapy ) within 4 week ( 28 day ) start study treatment ( within 12 week anti CCR4 antibody anti CD20 antibody ) . Has receive radiation therapy within 4 week ( 28 day ) start study treatment . Has multiple primary malignancy , EXCEPT adequately resect nonmelanoma skin cancer , curatively treat insitu disease , solid tumor curatively treat , evidence disease ≥5 year . Has concomitant treatment strong/moderate inhibitors/inducers cytochrome P450 3A4 ( CYP3A4 ) . Is unwilling use doublebarrier contraceptive measure avoid intercourse study least 3 month last dose DS3201b . Is lactate mother , pregnant confirm pregnancy test perform within 14 day registration . Prior treatment EZH inhibitor Has concomitant medical condition would increase risk toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Relapsed non-hodgkin lymphoma .</keyword>
	<keyword>phase 1</keyword>
	<keyword>oncology</keyword>
</DOC>